Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials

Authors Cooper C, Anzueto A, Decramer M, Celli B, Tashkin D, Leimer, Kesten

Published 9 May 2011 Volume 2011:6 Pages 269—275


Review by Single-blind

Peer reviewer comments 3

Christopher B Cooper1, Antonio Anzueto2, Marc Decramer3, Bartolome Celli4, Donald P Tashkin1, Inge Leimer5, Steven Kesten6
1David Geffen School of Medicine, University of California, Los Angeles, CA; 2University of Texas Health Science Center, South Texas Veterans Health Care System, San Antonio, TX; 3University of Leuven, Leuven, Belgium; 4Women's and Brigham Hospital, Boston, MA; 5Boehringer Ingelheim International GmbH, Ingelheim, Germany; 6Uptake Medical Corp, Tustin, CA, USA

Background: Data have highlighted the potential bias introduced by withdrawal of inhaled corticosteroids at randomization in chronic obstructive pulmonary disease trials examining inhaled corticosteroids. Analyses were conducted to determine whether this was true of inhaled anticholinergic withdrawal in tiotropium trials.
Methods: A pooled analysis of randomized, double-blind, placebo-controlled, parallel-group tiotropium trials of at least six months' duration was performed. Trials had similar inclusion and exclusion criteria. Exacerbation definition was standardized. Patients were divided into two groups, ie, D (anticholinergics discontinued at randomization, previously prescribed) and ND (anticholinergics not discontinued, not previously prescribed).
Results: Demographics were balanced between the D (n = 5846) and ND (n = 6317) groups, except for higher cumulative smoking (56 pack-years versus 48 pack-years), lower forced expiratory volume in one second (FEV1)/forced vital capacity (43% versus 48%), and lower baseline FEV1 (35.8% predicted versus 42.4% predicted) in the D group. In both groups, tiot ,ropium reduced the risk for an exacerbation (hazard ratio [HR] = 0.83, P < 0.0001 [D] versus 0.79, P < 0.0001 [ND]) and a hospitalized exacerbation (HR = 0.85, P = 0.0467 versus 0.79, P = 0.0094). Tiotropium reduced the number of exacerbations per patient-year (rate ratio [RR] = 0.82, P < 0.0001 [D] versus RR = 0.80, P < 0.0001 [ND]) and associated hospitalizations per patient-year (RR = 0.88, P = 0.015 [D] versus RR = 0.74, P < 0.0001 [ND]).
Conclusion: Tiotropium reduced exacerbations in patients who did and did not have anticholinergics discontinued upon randomization in clinical trials.

Keywords: chronic obstructive pulmonary disease, clinical trials, exacerbations, inhaled anticholinergics, tiotropium

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Development and implementation of treadmill exercise testing protocols in COPD

Christopher B Cooper, Marlon Abrazado, Daniel Legg, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:375-385

Published Date: 12 October 2010

Readers of this article also read:

Whole-body vibration improves functional capacity and quality of life in patients with severe chronic obstructive pulmonary disease (COPD): a pilot study

Braz Júnior DS, Dornelas de Andrade A, Teixeira AS, Cavalcanti CA, Morais AB, Marinho PE

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:125-132

Published Date: 12 January 2015

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:573-581

Published Date: 9 November 2011

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients

Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini E, Olivieri D

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:503-509

Published Date: 4 October 2011

Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations

Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:449-456

Published Date: 6 September 2011

Bronchodilation improves endurance but not muscular efficiency in chronic obstructive pulmonary disease

van der Vaart H, Postma DS, Grevink R, Roemer W, ten Hacken NHT

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:229-235

Published Date: 8 April 2011

Hypoxemia in patients with COPD: cause, effects, and disease progression

Brian D Kent, Patrick D Mitchell, Walter T McNicholas

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:199-208

Published Date: 14 March 2011

Economic burden of chronic bronchitis in the United States: a retrospective case-control study

Christopher M Blanchette, Melissa H Roberts, Hans Petersen, et al 

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:73-81

Published Date: 13 January 2011